SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969; 23: 198-202.
  • 2
    Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981; 141: 586-589.
  • 3
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318; discussion: 18-21.
  • 4
    Scheele J, Altendorf-Hofmann A. Resection of colorectal liver metastases. Langenbecks Arch Surg. 1999; 384: 313-327.
  • 5
    Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990; 77: 1241-1246.
  • 6
    Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224: 509-522.
  • 7
    Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000; 231: 480-486.
  • 8
    Hewitt PM, Dwerryhouse SJ, Zhao J, Morris DL. Multiple bilobar liver metastases: cryotherapy for residual lesions after liver resection. J Surg Oncol. 1998; 67: 112-116.
  • 9
    Wallace JR, Christians KK, Pitt HA, Quebbeman EJ. Cryotherapy extends the indications for treatment of colorectal liver metastases. Surgery. 1999; 126: 766-772; discussion: 72-74.
  • 10
    Gruenberger T, Jourdan JL, Zhao J, King J, Morris DL. Echogenicity of liver metastases is an independent prognostic factor after potentially curative treatment. Arch Surg. 2000; 135: 1285-1290.
  • 11
    Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306: 752-755.
  • 12
    Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992; 10: 896-903.
  • 13
    Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta Analysis Project. J Clin Oncol. 1994; 12: 960-969.
  • 14
    De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15: 808-815.
  • 15
    Breedis C, Young C. The blood supply of neoplasms in the liver. Am J Pathol. 1954; 30: 969-985.
  • 16
    Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984; 53: 1336-1343.
  • 17
    Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994; 12: 2288-2295.
  • 18
    Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978; 38: 3784-3792.
  • 19
    Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984; 2: 498-504.
  • 20
    Martin JK Jr., O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg. 1990; 125: 1022-1027.
  • 21
    Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987; 107: 459-465.
  • 22
    Allen-Mersh T, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994; 344: 1255-1260.
  • 23
    Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989; 7: 1646-1654.
  • 24
    Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987; 206: 685-693.
  • 25
    Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992; 10: 1112-1118.
  • 26
    Harmantas A, Rotstein L, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer. 1996; 78: 1639-1645.
  • 27
    Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst. 1996; 88: 252-258.
  • 28
    Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol. 1992; 10: 904-911.
  • 29
    Nag S, King J, Zhao J, Gebski V, Clingan P, Morris D. Prognostic factors in patients with colorectal liver metastases undergoing regional chemotherapy. HPB. in press.
  • 30
    Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983; 10: 176-182.
  • 31
    Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer. 1989; 63: 742-747.
  • 32
    Seifert J, Morris D. Pretreatment echogenicity of colorectal liver metastases predicts survival after hepatic cryotherapy. Dis Colon Rectum. 1999; 42: 43-49.